Heart Failure Management in Azerbaijan

Heart Failure Clinical Trial

— CHF-AZ  

Official title:

The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03390088
• Other study ID #: 2018-1
• Status: Withdrawn
• Start date: January 28, 2018
• Est. completion date: January 14, 2020

Study information

• Verified date: February 2020
• Source: World Heart Failure Society
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is proposed to determined a national database of the etiologies, clinical and the demographic profile, using diagnostic tests and treatment of outpatients with chronic heart failure in Azerbaijan population.

Description:

Chronic heart failure remains the leading cause of hospitalization for those over the age of 65 and expected to increase over the next 25 years with advancing life span. Being a progressive syndrome, CHF decreases the quality of life and place an economic burden on health care system.

Advanced technologies in interventional cardiology, better organization of angiographic laboratories and primary prevention of coronary artery disease as the leading cause of HF, allowed warning its development in CAD patients. But the incidence and prevalence of CHF continue to increase with age as heart failure with preserved ejection fraction predominates in elderly patients. For the moment more than 23 million people over the world suffer from heart failure.

The prevalence of these patients remains very high even in USA - over 5.8 million.However, there is no any database for heart failure patient in Azerbaijan.The purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests and management of outpatients heart failure in Azerbaijan population.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 14, 2020
• Est. primary completion date: December 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion :

• Patients >18 years olds

• Clinical diagnosis of heart failure

• NYHA class II-IV heart failure

Exclusion :

• Patients <18 years old

• Failure to obtain informed consent

• Pregnant or lactating

Previous cardiac transplantation

Related Conditions & MeSH terms

• Heart Failure

Locations

Country	Name	City	State
Azerbaijan	Yasmin Rustamova	Baku

Sponsors (1)

Lead Sponsor	Collaborator
Prof. Dr. Mehdi Zoghi

Country where clinical trial is conducted

Azerbaijan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Heart failure related hospitalization	Heart failure related hospitalization within 6 months	6 months